Program
Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628
Its studies are mostly in Neoplasm Metastasis, led by Exelixis.
Furthest: phase 1, since Apr 23, 20251 company-led study, 1 open or runningNext primary completion: May 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Exelixis | 11 open or running | phase 1since Apr 23, 2025 | Apr 23, 2025 | May 31, 2027phase 1 · NCT06952010 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 23, 2025First study: phase 1 study in Neoplasm MetastasisFirst studyNCT06952010 · 303 planned · United States
Ahead
- May 31, 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT06952010
TargetBeta
“A natural killer (NK) cell engager and bispecific antibody directed against the human NK and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (KLRC1; NK group 2 member A; NKG2A) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; clus”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06952010Neoplasm Metastasis · United States | 1 | Recruiting | May 31, 2027 | 303 |
How it is read
Names in the registry
- “XB628”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.